1. Introduction
Tetracyclines (TCs) are a large family of antibiotics that are used both within veterinary and therapeutic rehearsals [
1]. Tigecycline (TIGC), as shown in
Scheme 1, is the newest member of the tetracycline family that belongs to its third generation [
2,
3]. TIGC is the first antibacterial drug to be classified under glycylcyclines [
4]. Until 2019, TIGC was listed as an ‘essential medicine’ by the World Health Organization (WHO) [
5,
6]. As a (9-
t-butylglycylamido) derivative of the parent minocycline, TIGC possesses an enhanced ability to overcome the two resistance mechanisms that the TCs could encounter: ribosomal protection and the TC-specific efflux pump acquisition [
7].
In this itinerary, TIGC is a broad-spectrum antibiotic that kills bacterial cells by inhibiting protein synthesis. TIGC is commonly utilized to cure several diseases such as those caused by skin and intra-abdominal pathogens [
7]. Yet, first and foremost, TIGC is used to cure infections instigated by multiple-drug resilient pathogens [
8]. Recently, TIGC has been considered as a promising candidate for treating acute myeloid leukemia [
9]. With an unknown influence on the emergence of resistance in hospitalized patients and low possibilities for renal and other organ toxicity, the use of TIGC could help reduce the hospital burden on the other broad-spectrum antimicrobials [
7]. Nevertheless, the administration of TIGC was related to some incidents of unknown deaths. As of 2010, a black box warning for TIGC was consequently released [
10]. As a result, the use of TIGC as a last-resort drug was reserved for conditions in which an alternate treatment is not suitable. Moreover, with the release of TIGC into aquatic bodies that likely contain the
Tet(X) gene, the degradation of this antibiotic possibly causes the further emergence of microbial resistance [
2,
3,
11].
Therefore, finding a simple and sensitive approach for sensing even ultra-low concentrations of TIGC is crucial. A survey of the literature shows that the majority of the efforts in this regard were dedicated to studying TIGC in terms of its mechanism of action, pharmacokinetics, and pharmacodynamics, with fewer efforts being dedicated to finding a simple analytical technique for the determination of TIGC. The reported techniques mainly included chromatographic-based approaches [
12,
13,
14,
15,
16] and to a lesser extent spectrophotometric [
17] and spectrofluorimetric [
18,
19] approaches. By and large, the chromatographic approaches are sophisticated and require well-trained staff. Moreover, and to the best of our information, all the reported techniques for the analysis of TIGC were univariate-based, where a single variable is investigated at a time while the rest are kept constant. Employing this practice for optimizing process variables implies the absence of the overall vision of the process with a greater consumption of chemicals and resources.
Charge transfer complexes (CTC) are usually formed via molecular interactions of electron donors and electron acceptors with the subsequent development of a colored complex that exhibits different behaviors and properties [
20,
21,
22]. 7,7,8,8-tetracyanoquinodimethane (TCNQ) is a strong electron acceptor with four cyano-groups and a π-conjugation system, as shown in
Scheme 2 [
21].
In the current study, TCNQ will be used as the π-acceptor to react with TIGC as an electron donor to produce an intensely colored CTC. The approach we are offering herein is unique in terms of utilizing CTC for the sensitive and selective determination of TIGC, as well as being the first multivariate-based approach for the determination of TIGC with all the benefits this platform offers. In addition to saving time, efforts, and lowering the possible number of experimentations, a huge amount of data will be generated, an issue that helps to illustrate the reaction under investigation. Therefore, the conclusions can be considered highly irrevocable. It is noteworthy to mention that the Plackett–Burman design (PBD) is a two-level fraction factorial screening design that is used when only the main variables are concerned [
23,
24,
25,
26].
The aim of this work is to determine TIGC in its pure form and in the pharmaceutical dosage forms via a sensitive and selective spectrochemical approach. Moreover, the optimum conditions that maximize the reaction response, absorbance in this case, can be realized using PBD as a strategy. In this itinerary, four variables (temperature, reagent volume ‘RV’, reaction time ‘RT’, and the diluting solvent ‘DS’) will be assessed. One response variable will be measured: absorbance at 843 nm (Y
ctc). Therefore, the optimized approach can be applied in quality control and quality assurance laboratories especially in developing countries where the chance of using sophisticated approaches such as chromatography is not always plausible. Job’s method of continuous variation will be applied to determine the best stoichiometry for the TIGC-TCNQ interaction [
27]. The limits of detection (LOD) and quantification (LOQ) will be determined and the whole process will be assessed in terms of accuracy, precision, repeatability, ruggedness, and will follow the International Conference of Harmonization (ICH) recommendations [
28].
3. Materials and Methods
3.1. Instrumentation and Software
The software employed to constitute the PBD matrix was Minitab®19 (Minitab® Inc., State College, PA, USA). Deionized water utilized in the current investigation was obtained from a Millipore-Q water system (Burlington, MA, USA). Absorbance was determined by means of a UV-Vis spectrophotometer (Agilent diode-array, Agilent, Santa Clara, CA, USA) equipped with 10 mm quartz cuvettes (matched). Samples were heated to the required temperatures when needed using a thermostatically controlled water bath.
3.2. Reagents and Standards
Stock solutions of TIGC (0.05%) and TCNQ (0.1%) were freshly prepared daily by weighing specific amounts of TIGC and TCNQ powders and diluting them with acetonitrile to the mark in 100 mL volumetric flasks. Working solutions were obtained via serial dilutions of the stock solutions using the same solvent.
3.3. Materials
Tigecycline (TIGC, Batch# AT108181901) was the product of Biosynth® Carbosynth Ltd. (Compton, Berkshire, UK). The electron acceptor 7,7,8,8-tetracyanoquinodimethane (TCNQ, purity 98%) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Acetonitrile procured from BDH Chemicals (BDH Laboratory Supplies, Poole, UK) and methanol from Merck KGaA (Darmstadt, Germany) were used as received with no further purification. Tygacil® vials were purchased from local pharmacy stores in Cairo, Egypt.
3.4. General Procedures
3.4.1. Authentic Samples: Design of Experiments (DoE)
The studied variables and their proposed levels are listed in
Table 1. Twenty-four experimental runs took place (with 4 center points). Aliquots of 0.05% stock solution (500 µg mL
−1 of TIGC) were used in all experimental runs. A volume of 0.1% TCNQ, as shown in the scenario revealed in
Table 2, was added to TIGC solution and volume was completed to the mark using the suitable diluting solvent. Type of diluting solvent, temperature at which reaction took place, and the reagent volume are all shown for each run in the design matrix table, as shown in
Table 2. Reagent blanks were prepared and measured similarly. The absorbance of the resulting green colored solutions was measured at λ
max = 843 nm. To create the calibration curve, different concentrations of the stock solution were prepared from the TIGC stock solutions by serial dilution to obtain a final concentration in the range of 0.5–10 µg mL
−1, and the calibration curve was constructed using the same procedure and implementing the optimal conditions.
3.4.2. Procedure for the Formulation
Tygacil® vials (product of Patheon Italia S.P.A., Italy), labelled to contain 50 mg TIGC per vial, were the formulation of choice. The lyophilized content of the vial was further crushed and an amount of 30.8 mg of the powdered material (equivalent to 10.0 mg TIGC) was accurately weighed, dissolved in ACN, filtered, and transferred into a 50 mL volumetric flask. The volume was completed using ACN and formulation stock solution of 200 µg mL−1 TIGC was then ready for further analysis.
3.4.3. Standard Addition Method
Ten samples were made by inserting a fixed amount of 30 µL (200 µg mL−1) of the formulated drug solution to ten volumetric flasks (labelled as S0–S10). Different volumes (10–180 µL) of TIGC (0.05%) were then added followed by applying the optimum conditions and measuring the absorbance at λmax = 843 nm.
3.4.4. Procedure for Job’s Method
Job’s method [
27] was applied to ascertain the molar ratio for the interaction of TIGC with TCNQ. Equimolar solutions (0.854 mM) of TIGC and TCNQ were prepared. A total of ten samples (10 mL) were prepared where the total volume was kept at 2.0 mL of both drug and reagent for each solution, with the aid of acetonitrile as a solvent. Absorbance of the prepared set was recorded at λ
max = 843 nm contrasted to a reagent blank.
3.4.5. Evaluation of the Thermodynamic Parameters
Samples were prepared by keeping [TIGC] at least five times that of >[TCNQ], [D] >> [A], where D is the electron donor and A is the electron acceptor. Four sets with five samples each were prepared in volumetric flasks (10 mL). Volumes (1–3 mL) of 0.85 mM TIGC were inserted. Volume of 1.0 mL of 0.17 mM of TCNQ was then added. Solutions were then inserted in water bath for 60 min at 25, 40, 55, and 70 °C, followed by a measurement of the absorbance at 843 nm.
3.4.6. Investigation of the Reaction Kinetics
Seven sets were prepared with a [TIGC] of 1–8 µg mL−1. Absorbance of every group was recorded at 5, 15, 30, 45, 60, 75, and 90 min as described under the general procedure.
4. Conclusions
A simple, sensitive, and selective methodology was developed to generate a CTC involving tigecycline as the electron donor and TCNQ as a π- acceptor. The Plackett–Burman Design (PBD) was implemented to attain the optimum process variables and the maximum response—absorbance of the CTC in this case. A Pareto chart and ANOVA testing were used to determine the statistical significance of the studied variables. The results showed that the RV was not statistically significant. The desirability function plot showed that the optimum conditions that could be used to maximize the response were Temp: 25 °C, RV: 0.50 mL, RT: 60 min, and ACN as DS. Job’s method of continuous variation showed that the complex has a molecular composition of 1:1. ICH recommendations were used to assess the developed technique. The obtained data show excellent accuracy and precision with no significant differences compared to the reference method. Interferences from the common excipients and additives were not observed. Therefore, the developed approach could be utilized for the routine analysis of tigecycline in its pure form and in formulations. The calibration curve obtained under the optimum conditions was rectilinear in the range 0.5–10 µg mL−1. The stability of the CTC complex was determined using thermodynamic studies; thus, the Benesi–Hildebrand equation and Van’t Hoff plots showed the formation of a stable complex with a formation constant of 1.05 × 104 − 7.90 × 104 L mol−1 and a molar absorptivity of 4.96 × 104 − 8.89 × 104 L mol−1 cm−1. The Reaction kinetics were studied and revealed that the interaction between TIGC and TCNQ follows a pseudo-first-order reaction, and the best linearity was obtained at RT: 60 min.